Glycerophosphocholine (GPC) is a poorly understood biomarker in breast cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 38, 2012, Pages

  Moestue, Siver Andreas ^a   Giskeødeg̊ard, Guro F ^a   Cao, Maria D ^a   Bathen, Tone F ^a   Gribbestad, Ingrid S ^a  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CHOLINE; GLYCEROPHOSPHORYLCHOLINE;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; HUMAN; LETTER; METASTASIS POTENTIAL; NONHUMAN; PHOSPHOLIPID METABOLISM; PRIORITY JOURNAL; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER;

ANIMALS; BREAST NEOPLASMS; CHOLINE; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; OVARIAN NEOPLASMS; PHOSPHOLIPASES; PHOSPHORIC DIESTER HYDROLASES;

EID: 84866552299     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1208226109     Document Type: Letter

References (5)

1. Stewart JD, et al. (2012) Choline-releasing glycerophosphodiesterase EDI3 drives tumor cell migration and metastasis. Proc Natl Acad Sci USA 109:8155-8160.
2. Giskeødegård GF, et al. (2010) Multivariate modeling and prediction of breast cancer prognostic factors using MR metabolomics. J Proteome Res 9:972-979.
3. Moestue SA, et al. (2010) Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models. BMC Cancer 10:433.
4. Cao MD, et al. (2012) Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy. BMC Cancer 12:39.
5. Cao MD, et al. (2012) Predicting long-term survival and treatment response in breast cancer patients receiving neoadjuvant chemotherapy by MR metabolic profiling. NMR Biomed 25:369-378.